Post-study treatment does not influence outcome in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer

1. Borner, M.
2. Cassidy, J.
3. Cervantes, A.
4. Koralewski, P.
5. Zaluski, J.
6. Schuller, J.
7. Husseini, F.
8. Teller, S.
9. Twelves, C.